(Q43251199)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Francesco Recchia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Ferdinando Di Orio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Giampiero Candeloro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Gabriele Guerriero

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Juan Piazze

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

English

0 references

publication date

31 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

202-207

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

The management of recurrent ovarian cancer

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Managing minimal residual malignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

VEGF as a mediator of tumor-associated immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Interleukin-2: inception, impact, and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

The effects of 13-cis-retinoic acid and beta-carotene on cellular immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Optimal two-stage designs for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherap

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Ovarian cancer-derived glycodelin impairs in vitro dendritic cell maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Global Role of the Immune System in Identifying Cancer Initiation and Limiting Disease Progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

A highly potent antiangiogenic activity of retinoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.042

10.1016/J.YGYNO.2009.09.042

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880164%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference